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ABSTRACT 
Aim: To investigate anxiety levels and patient perception associated with supraventricular 
tachycardia (SVT); investigate anxiety levels and patient perception pre- and post- radiofrequency 
catheter ablation (RFCA); and explore any association between anxiety and patient perception 
with patient age and gender.  
Design: Follow-up quantitative and qualitative cohort study. 141 patients in a tertiary centre in 
Scotland who underwent an electrophysiological study and RFCA for atrioventricular nodal re-
entrant tachycardia, atrioventricular re-entrant tachycardia or atrial tachycardia between 2009 and 
2012 were enrolled. 59 (41.8%) were male; mean age at follow-up was 50 years. 
Interventions: Follow-up by structured phone questionnaire; mean follow-up period was 14 
months.  
Main outcome measures: Anxiety level and patient perception during index episode, and 
anxiety level before and after RFCA.  
Results: During index episode, median patient anxiety, on a scale of 0–10, was 8. Anxiety was 
not associated with gender (p = 0.07). Patients in the lowest and highest anxiety groups tended to 
be older (mean 54.5 and 44.4 years respectively) compared with those in the middle 2 groups 
(mean 34.1 and 35.6 years). There was an association between anxiety and age (p = 0.039). 45 
(32.0%) participants thought they were having a heart attack or dying. Before RFCA, median 
anxiety level was 7. 55 (39.0%) patients were afraid of complications, 21 (14.9%) patients feared 
being awake during RFCA. After RFCA, median anxiety was 2.5. 
Conclusions: Anxiety is a common accompaniment to SVT that may lead to greater pre-
procedural anxiety. Exploring this link may allow reduction of anxiety via better 
psychopharmacological intervention, education, and preprocedural counselling. 
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Supraventricular Tachycardia 
and Catheter Ablation: 
Anxiety Levels and Patient 
Perceptions 
Introduction 
Supraventricular tachycardia (SVT) 
encompasses a group of common 
paroxysmal tachyarrhythmias. SVT occurs in 
all age groups, and its mechanism varies 
depending on patient demographics.1 
Prevalence is around 2.25 per 1000 in the 
general population.2  
Atrioventricular nodal re-entrant tachycardia 
(AVNRT) is the commonest cause of 
paroxysmal SVT, accounting for 50–60% of 
diagnoses.3,4 It is more prevalent in young 
females.5 The AV node usually has a single 
conducting pathway whereby impulses travel 
to reach the bundle of His and cause 
contraction of the ventricles of the heart. 
Dual conduction pathways may coexist in 
some individuals and premature atrial 
impulses travelling along the secondary 
pathway may trigger episodes of AVNRT. 
Other mechanisms of SVT include 
atrioventricular re-entrant tachycardia, 
which includes Wolff–Parkinson–White 
syndrome and atrial tachycardia; a rare 
mechanism occurring in individuals with 
complex or structural heart disease 
particularly due to iatrogenesis or digoxin 
toxicity.6-8  
Presentation of SVT can range from an 
asymptomatic presentation and anxiety to 
shortness of breath, syncope, and chest 
pain. Palpitations are present in 96% of 
presentations.9,10 Although SVT is not 
usually life threatening, many patients suffer 
recurrent symptoms that have a significant 
impact on their quality of life. Many have 
symptoms for a prolonged period of time 
before diagnosis. Episodes are commonly 
misdiagnosed as panic attacks.11-13  
Radiofrequency catheter ablation (RFCA) is 
the first-line therapy for many SVTs, usually 
performed as a day-case procedure using 
conscious sedation. The efficacy of RFCA 
exceeds that of medical therapy, with 
success rates of around 95%.14 The 
procedure involves insertion of an ablation 
catheter, usually via the femoral vein, 
allowing for focal ablation of a critical 
component of the arrhythmic mechanism – 
such as an accessory pathway – using heat 
generated from high frequency alternating 
current.  
Hypothesis 
We hypothesize that 1) patients with SVT 
experience high levels of anxiety during their 
index episode and many believe they are 
experiencing a cardiac event; 2) anxiety 
levels are greater in female patients; 3) 
anxiety levels are greater in older patients; 
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and 4) RFCA considerably reduces anxiety 
levels in patients with SVT.  
The uncertain and sporadic nature of 
paroxysmal SVT can cause considerable 
anxiety. This paper primarily aims to 1) 
explore anxiety levels and patient 
perceptions at index episode (the first 
episode at which patients experience 
symptoms); 2) investigate any association 
between age or gender and anxiety; 3) 
explore anxiety and patient perceptions 
prior to RFCA; and 4) determine the impact 
of RFCA on patient anxiety. The secondary 
aim is to investigate an association between 
symptoms experienced during the index 
episode and anxiety. This is the first paper 
to assess anxiety during the index episode 
and explore patients’ thoughts. The 
relationship between cardiovascular disease 
and psychopathology has been explored in 
previous literature.15-17 Therefore, the 
purpose of this study is to identify a 
hypothetically presumed anxiety 
symptomatology, allowing for adequate 
indication for psychopharmacological 
intervention and thus a potential reduction 
in morbidity in patients with SVT. 
Methods 
Study population 
180 patients who had undergone an 
electrophysiological study (EPS) and RFCA 
for AVNRT, atrioventricular re-entrant 
tachycardia, or atrial tachycardia at the Royal 
Infirmary of Edinburgh, a tertiary hospital 
with a cardiac centre in the UK, between 1 
January 2009 and 1 January 2012 were 
approached to participate via an invitation 
letter. Simple random sampling was used to 
determine the sample size. Information 
regarding the mechanism of each patient’s 
SVT was collected from their EPS report via 
the TOMCAT database, which includes 
information on patients that have 
undergone EPSs and RFCA. Exclusion 
criteria were active organic brain disease, 
such as dementia or cerebral vascular 
disease, and history of psychiatric illness. Of 
the 180 patients identified, telephone 
numbers were obtainable in 148 cases and 
141 patients agreed to participate. 7 refused 
or did not respond. 59 male and 82 female 
patients took part, with an age range of 19–
92 years (median 52 years).  
Follow-up and data collection 
The mean follow-up period was 14 months 
(range 3.2–39.1 months). Telephone 
interviews lasted an average of 5 minutes 
and consisted of a structured clinical 
interview (see Appendix for clinical 
questionnaire). Questions were designed to 
explore patient anxiety levels during their 
index episode, and before and after RFCA, 
using a subjective scale of 0–10 (where 0 
indicates no anxiety and 10 indicates 
maximum anxiety). Patient perceptions of 
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their first episode of SVT and thoughts 
prior to RFCA were investigated using 
open-ended questions. Patients were 
encouraged to provide further comments 
about their perceptions and concerns about 
their index episode and RFCA procedure. 
Patients were also encouraged to provide 
comments about the symptoms experienced 
during their index episode such as chest 
pain, shortness of breath, or dizziness.  
Statistical analysis  
Statistical analysis was conducted using 
SPSS software. Anxiety level during the 
index episode was divided into 4 categories: 
(1) no anxiety (0); (2) mild anxiety (1–4); (3) 
moderate anxiety (5–7); and (4) severe 
anxiety (8–10). Any association between 
anxiety level during index episode and the 
gender or age was analysed using the Mann–
Whitney test. Gender was divided into 2 
groups: male and female. Age was divided 
arbitrarily into 2 groups: “older” and 
“younger”, separated by the median age of 
52. Anxiety ratings were treated as ordinal 
data (values existing on an arbitrary scale) 
and ranked. The Mann–Whitney test was 
then used to assess the null hypothesis: that 
there would be no variation in anxiety 
between genders or age.  The most common 
answers regarding perceptions during the 
index episode were grouped into 6 
categories and less common answers were 
categorized under “other”.  
The ANOVA test was used to determine if 
there was any significance between age or 
anxiety level and patients’ perception of 
their index episode. Thoughts were divided 
into 2 categories: “dangerous” and 
“benign”, and compared with anxiety levels. 
The mean anxiety experienced was 
compared with patients’ thoughts prior to 
RFCA.  
Results 
Anxiety during index episode 
Out of 141 patients, median anxiety during 
index episode was 8. Anxiety was divided 
into 4 groups (Figure 1). Results showed 26 
(44.1%) of males and 48 (58.5%) of females 
experienced severe anxiety (≥ 8) during their 
index episode. There was no significant 
association between anxiety and gender (p = 
0.07) with a similar distribution of males and 
females amongst anxiety groups. 
 
Figure 1. Proportion of male and female patients 
experiencing anxiety during their index episode 
of SVT. Participants were categorized into 4 
groups depending on their anxiety level. 
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There was a significant association between 
age and anxiety during the first episode. 
Older patients showed greater anxiety (p = 
0.028). Patients that showed no anxiety 
during the index episode were excluded 
from this statistical test as the sample size 
was too small. (n = 2) (Figures 1&2). 
 
Patient perceptions during index episode  
45 (32.0%) participants thought they were 
having a heart attack or dying (Figure 3). Of 
these patients, 43 (95.6%) had an anxiety 
rating in the severe category (8–10). 
 
The mean anxiety level for patients who 
experienced chest pain during their index 
episode was 7.7, while patients who did not 
experience chest pain had a mean anxiety of 
6.8. 15 out of 28 patients (53.6%) who 
experienced chest pain during their index 
episode thought they were dying or having a 
heart attack. 
There was a significant association between 
age at first episode and patient perception, 
with older patients tending to think they 
were having a heart attack or dying and 
younger patients regarding their index 
episode as benign palpitation or as a result 
of overexertion (p = 0.004) (Figure 4). The 
“other” category included indigestion, 
menopause, medication, overexcitement, 
pregnancy, and fatigue as perceived causes 
of the index episode. There was a significant 
association between anxiety level and patient 
perception of their index episode (p <0.001). 
Patients showed a higher anxiety level if they 
thought they were having a heart attack or 
dying (Figure 4). 
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Figure 3. What patients thought was 
happening during their index episode. The 
'other' category included indigestion, 
menopause, medication, over excitement, 
pregnancy and fatigue as perceived causes of 
index episode.  
 
 
Figure 2. Mean age of participants during 
index episode of SVT, and their corresponding 
anxiety level. Participants have been 
categorized into 3 groups, depending on the 
level of anxiety experienced. 
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Patient anxiety pre- and post-RFCA 
Prior to RFCA, median patient anxiety was 
7. The most common cause of concern and 
the greatest median subjective anxiety score 
prior to RFCA was due to fear of 
complications. 55 (39.0%) patients were 
afraid of complications, while 21 (14.9%) 
patients noted a fear of being awake during 
the procedure (Figure 5). The median 
anxiety level after RFCA was 2.5. 
 
 
 
 
 
 
 
 
 
The “other” category included fear of 
hospital, needle phobias, concern over the 
induction of palpitation, and waiting a long 
period prior to the procedure. 
Discussion 
Anxiety affects a large proportion of SVT 
patients. Of the 141 patients interviewed in 
this study, 74 (52.5%) experienced severe 
anxiety, with a reported anxiety level at 
index episode of 8 or above. Anxiety levels 
were not affected by gender (p = 0.07), 
which is surprising as there is a higher 
prevalence of anxiety disorders in females,12 
although none of the patients in this study 
had any known pre-existing psychiatric 
disorders. Moreover, female patients were 
more likely to attribute their palpitation to 
excitement, medication, or menopause, and 
this may be the reason why the mean anxiety 
level is similar between the genders as the 
palpitation was perceived to be a ‘natural’ 
event. Current literature states that males 
perceive cardiac disease more negatively and 
thus portray more anxiety and depressive 
symptoms.18  
There was a significant association between 
anxiety during the index attack and patient 
age, as hypothesized (p = 0.028). Older 
patients reported higher anxiety levels 
whereas younger patients reported mild to 
moderate anxiety throughout their first 
attack. These variations may be due to 
individual symptom perception, or pre-
0
5
10
15
20
25
30
35
40
45
50
None Mild (1-4) Moderate (5-
7)
Severe (8-10)
Complications
Unsuccessful
procedure
Awake during
Nothing in
particular
Others
Figure 4. Mean patient age at index episode and the 
mean anxiety level associated with what patients 
thought was happening during their index episode. 
Figure 5. Number of participants with 
concerns about RFCA, categorized into 4 
groups corresponding to the level of anxiety 
experienced.  
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existing anxiety that may influence the 
formation of a threatening perception of 
SVT.19 This trend is further supported by 
the significant association between patients’ 
perception of their palpitation and age (p < 
0.004). Older patients are more likely to 
think they are having a heart attack or are 
dying, and are more likely to report 
symptoms and anxiety.20 Younger patients 
were more likely to think they were having a 
heart attack if their palpitation came on 
during or after exercise. SVT potentially 
affects patients differently in terms of their 
physical symptoms, such as frequency and 
duration of episodes, and recurrence of 
symptoms after ablation. As a result, 
patients react differently to their symptoms 
and have dissimilar thoughts on the quality 
of their health and their prognoses. A 
prospective study, assessing anxiety levels 
and severity and duration of symptoms from 
index episode to ablation, would be useful in 
assessing such a relationship. Further studies 
could investigate the difference in 
prevalence of anxiety between SVT patients 
and the general population. One previous 
study did not find an increased prevalence 
of anxiety in patients with SVT.21  
The median anxiety level prior to RFCA was 
highest in patients afraid of complications 
and of being awake during the procedure. 
Lack of information and fear of potential 
complications are known to cause high 
levels of anxiety.22,23 However, it could be 
argued that this is the case for any invasive 
procedure and not RFCA in particular. 
There is a paucity of research regarding the 
difference in periprocedural anxiety among 
different invasive procedures. Many 
patients, however, mentioned previously 
undergoing invasive procedures where they 
had felt less anxious, and reported that the 
notion of being awake during a procedure 
which targeted a vital organ such as the 
heart caused them concern. Other patients 
were anxious due to the complexity of the 
procedure and the potential complications, 
which would be irreversible and require 
further interventions like pacemaker 
implantation. Anxiety levels prior to RFCA 
in this study were higher than anticipated, 
perhaps indicating a greater need for 
preprocedural explanation and reassurance. 
Previous research has suggested including 
discussions of previous patient experiences 
or reassurance from the clinician prior to 
RFCA to alleviate patient anxiety.24 The idea 
of catheters entering the heart and ablating 
tissue will seem bizarre to patients, and the 
complexity of RFCA may require a more 
detailed explanation from the physician in 
order to alleviate patients’ health concerns in 
comparison with other invasive procedures. 
The significant decrease in patient anxiety 
from a mean of 7 to 2.5 highlights the 
efficacy of RFCA. Anxiety levels after 
RFCA have previously been characterized, 
with a dramatic improvement in quality of 
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life and anxiety levels.25 Invasive treatment 
of SVT may result in reduction of anxiety 
due to the placebo effect or due to ablation-
induced changes in the arrhythmia. Studies 
looking at the placebo effect of other 
invasive cardiac procedures show that they 
significantly alter the perception of pre-
existing symptoms and reduce anxiety26 and 
this is probably true for ablation procedures 
for atrial fibrillation27,28 despite recurrences 
of symptoms. Further studies are needed to 
clarify this issue. Anxiety levels after ablation 
should be measured at a set time after the 
procedure, rather than immediately after or 
at arbitrary times, to allow for valid 
comparison between patients.  
Implications for practice and policy 
Anxiety is an important cause of morbidity 
and increased utilization of medical care. It 
is important for medical students to 
appreciate the impact that psychopathology 
can have on pre-existing disease and its 
prognostic contribution to cardiovascular 
disease.29 Identifying a demographic pattern 
in patients who present with severe anxiety 
after SVT will allow for more efficient 
psychopharmacological intervention.  
Limitations  
Telephone interview was selected as the best 
method for collecting data compared with 
mailed questionnaires. The expected 
response rate was greater, therefore reducing 
response bias. Communicating over the 
phone allowed the interviewer to clarify any 
misinterpretations of the participants, thus 
improving the reliability of the results.30 
There was risk of recall bias with over- or 
under-reporting of anxiety levels. Patients 
may not accurately remember how anxious 
they were during their index episode and 
thus may have given inaccurate reports of 
their anxiety. To reduce bias, the interviewer 
was trained and the same interviewer was 
used in each case.  
The use of a subjective anxiety scale is a 
potential source of bias and is not the most 
reliable way of measuring anxiety, as it can 
vary depending on the individual and 
situation and, therefore, lead to unreliable 
results. Furthermore, results obtained from 
a subjective scale can be difficult to interpret 
because of the ordinal nature of the 
collected data. The use of a subjective scale, 
however, meant that a larger sample size 
was recruited. Furthermore, the high 
participation rate – 141 out of 148 (95.3%) – 
supports the use of a subjective scale due to 
its simplicity. Nonetheless, this study could 
be repeated using official psychiatric 
questionnaires such as the Generalized 
Anxiety Disorder assessment (GAD 7) and 
Social Anxiety Questionnaire for Adults 
(SAQ-A30) to allow for more valid results. 
This study provides a basis for further study. 
The ANOVA test was used in this study to 
determine associations between patient 
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anxiety and patient perceptions during their 
index episode. For this to be possible, 
perceptions had to be divided into 2 
categories. The division of patients’ 
thoughts into binary values – “dangerous” 
and “benign” – is potentially problematic. 
This could be avoided in further studies by 
simplifying the question regarding 
perceptions and asking patients if they felt 
that they needed to go to the hospital or 
not, then determining an association with 
anxiety between the 2 groups using the 
Mann–Whitney test. 
Conclusion 
The psychological health of patients is an 
important factor to take into account as 
anxiety and individual disease perception 
can have an impact on the severity of 
symptoms.31 Anxiety is a common 
accompaniment to SVT and is more 
prevalent in older patients, hence supporting 
this study’s hypothesis. However, there 
seems to be no association between gender 
and anxiety. Many patients believe that they 
are having a heart attack or dying during 
their index episode. The perceived 
complexity of RFCA commonly elicits 
periprocedural anxiety in patients, 
suggesting that this is a factor which could 
be targeted by better counselling and 
education of patients at the time of referral 
and review and prior to their procedure. 
RFCA can significantly reduce patient 
anxiety. 
Learning Points 
What is already known? 
 SVT is a common tachyarrhythmia that causes anxiety in many patients. 
 Misinterpretation of episodes is common and many SVTs are misdiagnosed as panic 
attacks. 
 Catheter ablation is the first-line treatment for SVTs and significantly reduces anxiety 
levels in patients.  
What does this study add? 
 This study explores patients’ anxiety during their index episode of SVT and provides 
details of patients’ perceptions of their first attacks.  
 As anxiety is a common problem associated with SVT, exploring this aspect will 
hopefully lead to cardiologists providing more counselling and improving patient 
education during the time of referral and review and prior to the catheter ablation 
procedure. 
 Reducing anxiety in SVT patients will drastically lessen the severity of physical 
symptoms and improve quality of life. 
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APPENDIX 
PATIENT INFORMATION SHEET 
SUPRAVENTRICULAR MECHANISMS AND THEIR AGE AND GENDER DISTRIBUTION 
You are being invited to take part in a research study. Before you decide, it is important for you to understand why 
this research is being done and what it will involve. Please take time to read the following information carefully and 
discuss it with others if you wish.  
What is the purpose of this study and why have I been chosen? 
You have been chosen out of a group of 180 patients because you have been seen in the cardiology clinic with an 
arrhythmia and have undergone ablation treatment. We are interested in hearing about your experience with your 
condition, both before and after your treatment.  
This study is designed to assess how patients’ lives are affected, both physically and psychosocially, by their 
condition. 
Do I have to take part? 
It is completely your choice whether or not to take part. If you do decide to join our study, you are still free to 
withdraw at any time and without giving a reason. A decision not to take part will not affect the standard of 
care you receive. 
What will happen to me if I take part and what are the potential risks? 
There is no risk involved in this study. Over the next few weeks, you will receive a phone call from us. We 
require around 10 minutes of your time, during which we will ask you to complete a short questionnaire over the 
phone. This questionnaire will assess your first experience of arrhythmia symptoms, how you felt at the time and 
your past medical history. It will also ask questions about your health, mood and experiences with your ablation 
treatment; both during and after the procedure. If you receive a call from us and feel that you do not have the 
time to answer questions at that moment, we would be happy to reschedule an interview.  
Will my taking part in the study be kept confidential? 
All information which is collected about you will be kept strictly confidential. Any information which leaves 
the hospital/surgery will have your name and address removed do that you cannot be recognised from it.  
What will happen to the results of the study? 
The results will form part of a research project which will be submitted to the University of Edinburgh Medical 
Faculty. It is hoped that the results will be submitted for publication to a medical journal. As stated above, all 
information will be kept anonymous.  
The results of the study will be made available to you should you require further information 
Thank you for your consideration of this study 
Dr. xxx is a consultant Cardiologist who is available to advise you about the study and participation if you require 
more information, and is contactable through the Royal Infirmary of Edinburgh switchboard: (0131 242 1000) 
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(2) Structured Clinical Interview 
How old were you when you had your first episode?  
What was the first thing you thought when palpitation started?  
How anxious did you feel during your first attack? (score of 0-10; 0 being 
not anxious at all and 10 being the most anxious you could be) 
 
 
How often do episodes 
occur? (With 
specification) 
 Daily  
 Once/twice per week  
 Once per fortnight  
 Once per month  
 Less than once per month   
How long do episodes 
last? 
 Minutes 
 Hours 
 Days 
What do you feel 
during palpitation? 
 
 Anxiety 
 Dizziness/light-headedness 
 Blackouts 
 Chest pain 
 Breathlessness 
 Other  
Have you ever 
indentified a trigger for 
your palpitation? (Y/N) 
 Stress 
 
 Alcohol 
 Caffeine 
 Tiredness 
 Exercise 
 Other  
Do you ever get palpitation when you are doing nothing/ no obvious trigger? 
(Y/N) 
Are you able to stop 
your palpitation 
yourself? (Y/N) 
 Breath-holding 
 Neck massage 
 Bending 
 Lying down 
 Other  
Did you take any 
medications before 
your RFCA? 
 Beta-blocker 
 Calcium channel blocker 
 Digoxin 
 Amiodarone 
 Flecanide 
 Aspirin 
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 Warfarin 
 Other  
Do you have any of 
the following health 
problems? 
 Depression/anxiety 
 Thyroid disease 
 IHD 
 Diabetes 
How anxious were you before your ablation? (0-10)  
What were you worried about?  
How anxious were you after the procedure? (0-10)  
Did you experience any pain at any point 
during the procedure? (Y/N) 
When?  
Pain (0-10)  
Did you feel breathless at all during the procedure? 
(Y/N) 
Did you feel dizzy at all? 
(Y/N) 
Any palpitation since your ablation? 
(Y/N) 
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